IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 3092 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (170 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Figures

 Article Access Statistics
    Viewed5042    
    Printed66    
    Emailed1    
    PDF Downloaded702    
    Comments [Add]    

Recommend this journal

 


 
ACNE IN INDIA: GUIDELINES FOR MANAGEMENT - IAA CONSENSUS DOCUMENT
Year : 2009  |  Volume : 75  |  Issue : 7  |  Page : 31-33

Topical antibacterials


members Indian Acne Alliance, India

Correspondence Address:
Raj Kubba
Consultant Dermatologist, Kubba Clinic,10, Aradhana Enclave, Ring Road, New Delhi - 110066
India
Login to access the Email id

Source of Support: Production and publication of this supplement is made possible by an educational grant from Galderma India Pvt. Ltd., Conflict of Interest: Indian Acne Alliance (IAA) meetings logistics to formulate IAA consensus document DQAcne in India: Guidelines for managementDQ were supported by Galderma India Pvt. Ltd.


PMID: 19282587

Rights and PermissionsRights and Permissions



How to cite this article:
Kubba R, Bajaj A K, Thappa D M, Sharma R, Vedamurthy M, Dhar S, Criton S, Fernandez R, Kanwar A J, Khopkar U, Kohli M, Kuriyipe V P, Lahiri K, Madnani N, Parikh D, Pujara S, Rajababu K K, Sacchidanand S, Sharma V K, Thomas J. Topical antibacterials. Indian J Dermatol Venereol Leprol 2009;75, Suppl S1:31-3

How to cite this URL:
Kubba R, Bajaj A K, Thappa D M, Sharma R, Vedamurthy M, Dhar S, Criton S, Fernandez R, Kanwar A J, Khopkar U, Kohli M, Kuriyipe V P, Lahiri K, Madnani N, Parikh D, Pujara S, Rajababu K K, Sacchidanand S, Sharma V K, Thomas J. Topical antibacterials. Indian J Dermatol Venereol Leprol [serial online] 2009 [cited 2019 Oct 15];75, Suppl S1:31-3. Available from: http://www.ijdvl.com/text.asp?2009/75/7/31/45478


Topical antibiotics: Current options include clindamycin, clarithromycin, azithromycin, and nadifloxacin. Tetracycline and erythromycin are no longer easily available. Topically applied antibiotics work slowly and are marginally effective. [1] They are rarely adequate as a monotherapy but are useful adjuncts to all forms of systemic and topical therapy. Their antibacterial, anti-inflammatory, and, possibly comedolytic effects [2] are optimized through careful determination of concentrations, and their suitability is enhanced by making them available in different forms, for example, creams, gels, solutions, pledgets, and sachets to cater to diverse skin types and changing dynamics of the skin brought about by changes in weather conditions, physical activities, and effects of concomitant therapies. Gels are preferable as they offer the best combination of being nonoily, invisible, and having good percutaneous absorption. In our country, topical antibiotics are generic and the selection is overwhelming. The bioequivalence of various products has not been addressed and it is left to the prescribing dermatologist to make that judgement. Further, topical products are more vulnerable to 'shelf-conditions' and this too impacts efficacy. There is much more to prescribing topical antibiotics. They should be applied to the entire area, in a quantity that readily absorbs, ideally twice daily. They may be used in conjunction with other topical products (sunscreens, moisturizers, retinoids, antifungals) but only after ascertaining compatibility. Topical antibiotics should be discontinued if no therapeutic benefit is observed in 6-8 weeks. [1] Resistance to topical antibiotics is frequent and extends to cross-resistance between commonly used antibiotics, especially tetracycline, erythromycin, and clindamycin. [1] Indiscriminate use of topical antibiotics is a major cause of bacterial resistance and should be curbed. [3] Other than occasional erythema, peeling, burning, itching, and dryness, topical antibiotics are well tolerated and safe. [1] There are rare reports of pseudomembranous colitis from topical clindamycin. [1] We are fortunate in India to have available newer topical antibiotics such as clarithromycin, azithromycin, and nadifloxacin. While clarithromycin and azithromycin, being macrolides, have quietly replaced erythromycin without much documentation, nadifloxacin is a brand new entrant and has been clinically evaluated in inflammatory acne. [4] Nadifloxacin is a fluorinated quinolone that inhibits DNA gyrase, and has strong antibacterial activity against Gram-negative and Gram-positive bacteria. [4] In a double-blind study comparing nadifloxacin 1% cream with erythromycin 2% cream in acne vulgaris, the two formulations were found to be equally effective at 12 weeks (66.7% versus 64.7%, respectively); however it was noted that while the erythromycin cream was only effective against P. acnes , nadifloxacin cream lowered counts of coagulase negative staphylococci as well as P. acnes . [5] Further, antibiotic resistance to nadifloxacin was extremely low compared to erythromycin. [5] Several formulations of nadifloxacin are available in our country, including a gel. Lessons from P. acnes resistance to erythromycin should alert us to the possibility of the same happening with clarithromycin and azithromycin?

Benzoyl peroxide: Benzoyl peroxide (BPO) is a safe and effective, time tested, agent in the treatment of acne. [1] In India, it is readily available as 2.5%, 5%, and 10% gel, as a wash, and as a bar soap. BPO gel is more stable and allows better release of the active ingredient. [1] Internationally, other concentrations (1-10%), and other formulations (cream, lotion, cleanser, soap) are available. [1] It is an excellent choice in the treatment of mild and moderate acne. [1] Its principal mode of action is antibacterial (possibly bactericidal?) and to a lesser extent as comedolytic. [1] BPO is more effective than topical erythromycin and clindamycin. [6] Combination of BPO and erythromycin or BPO and clindamycin is more effective than BPO alone and is less irritating. [7],[8] Topical BPO and BPO/erythromycin combination are deemed to be similar in efficacy to oral oxytetracycline and minocycline. [9] BPO has the advantage that bacterial resistance does not develop. [1] It can be used as monotherapy though it is more effective in combination (vide supra). It needs to be applied to the entire surface. It is better to initiate therapy at lower concentrations (2.5%) because there is a potential for irritation. Whenever irritation is encountered it can be overcome by gradual induction of the therapy. [5] Though used once daily generally, BPO may be applied twice daily. [1] BPO tends to bleach hair, clothing, and bed-linen, [10] and perilesional skin with spot treatment.

Topical metronidazole: In gel formulation, it is the first-line treatment for rosacea and is also useful in overlap cases - acne/rosacea, and acne treated with topical steroids (steroid rosacea) [Figure 57],[Figure 58]. Its mode of action is antibacterial and anti-inflammatory. In straightforward acne patients, it was found to be no more effective than placebo. [11]

Dapsone: Dapsone has previously been used as an oral adjunctive therapy for severe inflammatory acne. It has anti-inflammatory and antibacterial properties. Recently it has been possible to formulate it as 5% aqueous gel and it has been clinically evaluated in the USA. [12] In two large randomized studies involving 3010 subjects, dapsone gel was compared with the vehicle gel over 12 weeks. Dapsone-treated patients achieved superior results in reducing both inflammatory and noninflammatory lesions. The difference was apparent as early as two weeks. There were no systemic effects, and acne patients with G-6PD deficiency tolerated the dapsone gel. The studies concluded that dapsone 5% gel was effective, safe, and well-tolerated treatment for acne with rapid onset of action. [12] Our limited experience with dapsone gel, for the short period it was available in the Indian market, was not as favorable.

Azelaic acid: It is a naturally occurring dicarboxylic acid produced by the yeast fungus Pityrosporum ovale. It has antibacterial and anticomedonal properties and is felt by some to be equal in efficacy to BPO or tretinoin. [13],[14] The efficacy of azelaic acid may be increased by using it in combination with other topical medications such as retinoids, antibiotics, or BPO. Another beneficial effect of this agent is to decrease hyperpigmentation caused by acne. Azelaic acid is available as 10% and 20% cream and is to be applied twice daily. It frequently causes transient burning and tingling sensation, and occasionally mild erythema and pruritus.

 
  References Top

1.Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al . Management of acne: A report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003;49:S1-38.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Plewig G, Kligman AM. Acne and rosacea. 3 rd ed. New York: Springer-Verlag; 2000.  Back to cited text no. 2    
3.Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, et al . Antibiotic resistant acne: Lessons from Europe. Br J Dermatol 2003;148:467-78.  Back to cited text no. 3    
4.Kuwahara K, Kitazawa T, Kitagaki H, Tsukamoto T, Kikuchi M. Nadifloxacin: An antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. J Dermatol Sci 2005;38:47-55.  Back to cited text no. 4    
5.Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris, phase III comparison study versus erythromycin 2% cream. Eur J Dermatol 2006;16:48-55.  Back to cited text no. 5    
6.Eady EA, Cove JH, Joanes DN, Cunliffe WJ. Topical antibiotics for the treatment of acne vulgaris: A critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatol Treat 1990;1:215.  Back to cited text no. 6    
7.Lookingbill DP, Chalker DK, Lindholm JS, Katz HI, Kempers SE, Huerter CJ, et al . Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: Combined results of two double-blind investigations. J Am Acad Dermatol 1997;37:590-5.  Back to cited text no. 7    
8.Packman AM, Brown RH, Dunlap FE, Kraus SJ, Webster GF. Treatment of acne vulgaris: Combination of 3% erythromycin and 5% benzoyl peroxide in a gel compared to clindamycin phosphate lotion. Int J Dermatol 1996;35:209.  Back to cited text no. 8    
9.Ozolins M, Eady EA, Avery AJ, CunliffeWJ, Po AL, O'Neill C, et al . Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory acne vulgaris in the community: Randomized controlled trial. Lancet 2004;364:2188-95.  Back to cited text no. 9    
10.Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: Effects on the surface and follicular cutaneous microflora. Br J Dermatol 1995;132:204-8.  Back to cited text no. 10    
11.Tong D, Peters W, Barnetson RS. Evaluation of 0.75% metronidazole in acne: A double blind study. Clin Exp Dermatol 1994;19:221-3.  Back to cited text no. 11    
12.Draelos Z, Carter E, Maloney JM Elewski B, Poulin Y, Lynde C, et al . Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne. J Am Acad Dermatol 2007;56:439-47.  Back to cited text no. 12    
13.Batra RS. Acne, In: Arndt KA, Hsu JTS, editors. Manual of dermatologic therapeutics. 7th ed. New Delhi: Lippincott Williams and Wilkins; 2007. p. 3-18.  Back to cited text no. 13    
14.Feldman SR, Phelps KC, Verzino KC. Handbook of dermatologic drug therapy. London: Taylor and Francis; 2005. p. 3.  Back to cited text no. 14    


    Figures

  [Figure 57], [Figure 58]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow